Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Investor Presentation (March 2023)
22 slides from Lifemd's investor presentation, March 2023
Slide 1: The Doctor Will See You Now
The Doctor Will See You Now March 2023 NASDAQ: LFMD
Slide 2: Important Cautions Regarding Forward-Looking Statements
NASDAQ: LFMD Important Cautions Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the
Slide 3: Our Mission
Our Mission Empower people to live healthier lives by increasing access to affordable, high quality virtual and in-home healthcare
Slide 4: LifeMD At A Glance
NASDAQ: LFMD LifeMD At A Glance A transformational year, including new brands and partnerships, heightened focus on subscription-based virtual care platform, and achieved Q4’22 Adjusted EBITDA profitability. 200+ 130+ 1 $119m 675k 28% 2022A Patient Conditions Patient Care ’22 Revenue Revenue Consult
Slide 5: Our Patient-Centric Approach
NASDAQ: LFMD Our Patient- Virtual Care Centric Approach Comprehensive care including primary care, urgent care, and chronic LifeMD's integrative platform elevates the healthcare condition management. experience with seamless, end-to-end care spanning diagnosis, medication delivery, and ongoing care.
Slide 6: Our Growing LifeMD Ecosystem
NASDAQ: LFMD 50-State Telehealth Platform Marketing & E-Commerce Our Growing LifeMD Lab Services Ecosystem Pharmacy Adjudication & Powered by Strong Partners & Integrations Cash-Pay Medications Data & Analytics Customer Service 6
Slide 7: Facilitating The Future Of Virtual-First, In-Home Healthcare
NASDAQ: LFMD Facilitating The Future Of Virtual-First, In-Home Healthcare Advanced Patient Diagnostics & Prescription Symptom Education In-Home Labs Discount Card Checker In Home Supplement Clinical Virtual Consults Health Tools & Lifestyle Specialist & Messaging & Wearables 1 Routines Access 7 1. P
Slide 8: A Telehealth Platform Trusted By Over 675k Patients
NASDAQ: LFMD A Telehealth Platform Trusted By Over 675k Patients Best-in-Class Marketing & Scalable Providers Data Analytics Technology We attract and invest in Deep expertise in Our vertically integrated amazing medical providers performance marketing, platform is proven to that deliver incredible
Slide 9: Best-In-Class Providers
NASDAQ: LFMD Best-In-Class Providers Health Care Leadership Professionals Deep experience in 50 state coverage virtual and brick-and- by LifeMD affiliated mortar primary and doctors and NPs urgent care Multi-State Treatments Coverage Comprehensive, virtual 75% of clinicians care for hundreds of are
Slide 10: Experts In Marketing & Analytics
NASDAQ: LFMD Experts In Marketing & Analytics Proprietary technology platform that enables flexible acquisition strategies ~130 person call center in Greenville, SC that drives new acquisition and high touch patient care Custom built analytics platform that enables real- time reporting and decision
Slide 11: Proprietary & Scalable Tech Stack
NASDAQ: LFMD Proprietary & Scalable Tech Stack Designed to support a diverse portfolio of DTC and B2B telehealth product and service offerings Integrations with Quest, LabCorp, EMR, multiple pharmacies, in-home tools, symptom checker, prescription discount card, and more Designed with a compliance-f
Slide 12: Our Brands
NASDAQ: LFMD Our Brands ~$250B ~$44B ~$13.5B >$5.1B ~$2.8B market size market size market size market size market size ® ® Primary Care Dermatology Allergy & Asthma Men’s Health Hair Loss Primary care, urgent Dermatology Treatment, prescription Discreet and fast Treatment, care, chronic condition tr
Slide 13: Rapidly Expanding Telehealth Presence
NASDAQ: LFMD Rapidly Expanding Telehealth Presence 2019 2021 2022 DTC Telemedicine Virtual Primary Care B2B Solutions Subscription-based Services include primary care, Digital front-door treatment+Rx offerings urgent care, and chronic strategies for healthcare condition management product companies
Slide 14: Virtual Primary Care (VPC) Has Hit Its Stride And Is Rapidly Expanding
NASDAQ: LFMD Virtual Primary Care (VPC) Has Hit Its Stride And Is Rapidly Expanding End of Period VPC Patients ~ 7,000 7000 6000 5000 VPC Patients 4000 3000 2,400 2000 1,000 1000 420 45 101 0 Apr-22 May-22 Jun-22 Jul-22 Q3 22 Q4 22A 14
Slide 15: Early Mover Advantage, Supported By A Patient-Centric Approach, Has Enabled Incredible Growth
NASDAQ: LFMD Early Mover Advantage, Supported $119M By A Patient-Centric Approach, Has Enabled Incredible Growth $93M $119M 2022A Revenue Forecast 28% $37M YoY Revenue Growth in ‘22 $13M 675K+ Patients & Customers To-Date 2019A 2020A 2021A 2022A 15 198% 149% 28%
Slide 16: Meaningful Improvement in Cash Burn & Bottom-Line Performance
NASDAQ: LFMD Meaningful Improvement in Cash Burn & Bottom-Line Performance; Consolidated Profitability Achieved in Q4 '22 Consolidated Adjusted EBITDA ($ millions) $5.0 $0.6 $0.0 -$1.0 -$12.0 -$9.0 -$8.2 -$7.6 -$6.9 -$5.0 -$10.0 -$15.0 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022A Note: C
Slide 17: Rapidly Accelerating Gross Margins And Increasing Leverage On Marketing Spend
NASDAQ: LFMD Rapidly Accelerating Gross Margins And Increasing Leverage On Marketing Spend Driving Pathway To Profitability Consolidated Gross Margin % Marketing Cost as % of Sales 35 125% 90% 88% 32 100% Net Revenue ($ Millions) 86% 81% 77% 75% 72% 84% 29 75% 62% 82% 55% 80% 26 50% 78% 23 25% 76% 7
Slide 18: Full Year 2023 Guidance Reflecting Substantial Profitability Growth
NASDAQ: LFMD Full Year 2023 Guidance Reflecting Substantial Profitability Growth FY 2023 GUIDANCE FY 2022 ACTUAL DELTA % Consolidated Net Revenue $140-$150 million $119 million +18-26% Gross Margin % 87% 84% +300 bps Consolidated Adj. EBITDA $12-$18 million $(15) million +180-220% Free Cash Flow Bre
Slide 19: Strong Liquidity to Meet our Capital and Growth Needs
NASDAQ: LFMD Strong Liquidity to Meet our Capital and Growth Needs FY 2023 CASH FLOW GUIDANCE End of Year 2022 Actual Cash Balance $4 million Plus Avenue Capital FY23 Debt Proceeds, net +$18 million Operating Cash Flow (incl. Interest Expense) +$4-$8 million Less Capex $(6)-$(8) million Less Preferr
Slide 20: Management Team and Board of Directors
NASDAQ: LFMD Management Team Justin Schreiber Alex Mironov Marc Benathen Stefan Galluppi Brad Roberts Jessica Friedeman Chief Executive President Chief Financial Officer Chief Innovation & Chief Operating Officer Chief Marketing Officer Officer Marketing Officer Dr. Tony Puopolo James Porte Eric Yec
Slide 21: Investor Highlights
NASDAQ: LFMD Investor Highlights Significant presence within massive and growing addressable markets Proprietary technology platform differentiated by leading 50-state, affiliated physician network High margin products/services generating 85%+ consolidated gross margins EBITDA break-even with signif
Slide 22: Company Contact
Company Contact Marc Benathen [email protected]